Global Antisense and RNA Interference Therapeutics Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Antisense and RNA Interference Therapeutics Industry Forecast” looks at past sales and reviews total world Antisense and RNA Interference Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense and RNA Interference Therapeutics sales for 2023 through 2029. With Antisense and RNA Interference Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense and RNA Interference Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Antisense and RNA Interference Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antisense and RNA Interference Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antisense and RNA Interference Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense and RNA Interference Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense and RNA Interference Therapeutics.
The global Antisense and RNA Interference Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Antisense and RNA Interference Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Antisense and RNA Interference Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Antisense and RNA Interference Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Antisense and RNA Interference Therapeutics players cover Alnylam Pharmaceuticals, Antisense Therapeutics, Arbutus Biopharma, Ionis Pharmaceuticals, F. Hoffmann-La Roche, Santaris, Silence Therapeutics, Sirnaomics and Tekmira Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Antisense and RNA Interference Therapeutics market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Antisense and RNA Interference Therapeutics market?
What factors are driving Antisense and RNA Interference Therapeutics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antisense and RNA Interference Therapeutics market opportunities vary by end market size?
How does Antisense and RNA Interference Therapeutics break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Antisense and RNA Interference Therapeutics Industry Forecast” looks at past sales and reviews total world Antisense and RNA Interference Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense and RNA Interference Therapeutics sales for 2023 through 2029. With Antisense and RNA Interference Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense and RNA Interference Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Antisense and RNA Interference Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antisense and RNA Interference Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antisense and RNA Interference Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense and RNA Interference Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense and RNA Interference Therapeutics.
The global Antisense and RNA Interference Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Antisense and RNA Interference Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Antisense and RNA Interference Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Antisense and RNA Interference Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Antisense and RNA Interference Therapeutics players cover Alnylam Pharmaceuticals, Antisense Therapeutics, Arbutus Biopharma, Ionis Pharmaceuticals, F. Hoffmann-La Roche, Santaris, Silence Therapeutics, Sirnaomics and Tekmira Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Antisense and RNA Interference Therapeutics market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- RNA
- Antisense RNA
- General Hospitals
- Specialty Clinics
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Alnylam Pharmaceuticals
- Antisense Therapeutics
- Arbutus Biopharma
- Ionis Pharmaceuticals
- F. Hoffmann-La Roche
- Santaris
- Silence Therapeutics
- Sirnaomics
- Tekmira Pharmaceuticals
What is the 10-year outlook for the global Antisense and RNA Interference Therapeutics market?
What factors are driving Antisense and RNA Interference Therapeutics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antisense and RNA Interference Therapeutics market opportunities vary by end market size?
How does Antisense and RNA Interference Therapeutics break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antisense and RNA Interference Therapeutics Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Antisense and RNA Interference Therapeutics by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Antisense and RNA Interference Therapeutics by Country/Region, 2018, 2022 & 2029
2.2 Antisense and RNA Interference Therapeutics Segment by Type
2.2.1 RNA
2.2.2 Antisense RNA
2.3 Antisense and RNA Interference Therapeutics Sales by Type
2.3.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
2.3.2 Global Antisense and RNA Interference Therapeutics Revenue and Market Share by Type (2018-2023)
2.3.3 Global Antisense and RNA Interference Therapeutics Sale Price by Type (2018-2023)
2.4 Antisense and RNA Interference Therapeutics Segment by Application
2.4.1 General Hospitals
2.4.2 Specialty Clinics
2.5 Antisense and RNA Interference Therapeutics Sales by Application
2.5.1 Global Antisense and RNA Interference Therapeutics Sale Market Share by Application (2018-2023)
2.5.2 Global Antisense and RNA Interference Therapeutics Revenue and Market Share by Application (2018-2023)
2.5.3 Global Antisense and RNA Interference Therapeutics Sale Price by Application (2018-2023)
3 GLOBAL ANTISENSE AND RNA INTERFERENCE THERAPEUTICS BY COMPANY
3.1 Global Antisense and RNA Interference Therapeutics Breakdown Data by Company
3.1.1 Global Antisense and RNA Interference Therapeutics Annual Sales by Company (2018-2023)
3.1.2 Global Antisense and RNA Interference Therapeutics Sales Market Share by Company (2018-2023)
3.2 Global Antisense and RNA Interference Therapeutics Annual Revenue by Company (2018-2023)
3.2.1 Global Antisense and RNA Interference Therapeutics Revenue by Company (2018-2023)
3.2.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Company (2018-2023)
3.3 Global Antisense and RNA Interference Therapeutics Sale Price by Company
3.4 Key Manufacturers Antisense and RNA Interference Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antisense and RNA Interference Therapeutics Product Location Distribution
3.4.2 Players Antisense and RNA Interference Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTISENSE AND RNA INTERFERENCE THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Antisense and RNA Interference Therapeutics Market Size by Geographic Region (2018-2023)
4.1.1 Global Antisense and RNA Interference Therapeutics Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Antisense and RNA Interference Therapeutics Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Antisense and RNA Interference Therapeutics Market Size by Country/Region (2018-2023)
4.2.1 Global Antisense and RNA Interference Therapeutics Annual Sales by Country/Region (2018-2023)
4.2.2 Global Antisense and RNA Interference Therapeutics Annual Revenue by Country/Region (2018-2023)
4.3 Americas Antisense and RNA Interference Therapeutics Sales Growth
4.4 APAC Antisense and RNA Interference Therapeutics Sales Growth
4.5 Europe Antisense and RNA Interference Therapeutics Sales Growth
4.6 Middle East & Africa Antisense and RNA Interference Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Antisense and RNA Interference Therapeutics Sales by Country
5.1.1 Americas Antisense and RNA Interference Therapeutics Sales by Country (2018-2023)
5.1.2 Americas Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023)
5.2 Americas Antisense and RNA Interference Therapeutics Sales by Type
5.3 Americas Antisense and RNA Interference Therapeutics Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antisense and RNA Interference Therapeutics Sales by Region
6.1.1 APAC Antisense and RNA Interference Therapeutics Sales by Region (2018-2023)
6.1.2 APAC Antisense and RNA Interference Therapeutics Revenue by Region (2018-2023)
6.2 APAC Antisense and RNA Interference Therapeutics Sales by Type
6.3 APAC Antisense and RNA Interference Therapeutics Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antisense and RNA Interference Therapeutics by Country
7.1.1 Europe Antisense and RNA Interference Therapeutics Sales by Country (2018-2023)
7.1.2 Europe Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023)
7.2 Europe Antisense and RNA Interference Therapeutics Sales by Type
7.3 Europe Antisense and RNA Interference Therapeutics Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antisense and RNA Interference Therapeutics by Country
8.1.1 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Country (2018-2023)
8.1.2 Middle East & Africa Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023)
8.2 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Type
8.3 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antisense and RNA Interference Therapeutics
10.3 Manufacturing Process Analysis of Antisense and RNA Interference Therapeutics
10.4 Industry Chain Structure of Antisense and RNA Interference Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antisense and RNA Interference Therapeutics Distributors
11.3 Antisense and RNA Interference Therapeutics Customer
12 WORLD FORECAST REVIEW FOR ANTISENSE AND RNA INTERFERENCE THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Antisense and RNA Interference Therapeutics Market Size Forecast by Region
12.1.1 Global Antisense and RNA Interference Therapeutics Forecast by Region (2024-2029)
12.1.2 Global Antisense and RNA Interference Therapeutics Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Antisense and RNA Interference Therapeutics Forecast by Type
12.7 Global Antisense and RNA Interference Therapeutics Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Alnylam Pharmaceuticals
13.1.1 Alnylam Pharmaceuticals Company Information
13.1.2 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.1.3 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Alnylam Pharmaceuticals Main Business Overview
13.1.5 Alnylam Pharmaceuticals Latest Developments
13.2 Antisense Therapeutics
13.2.1 Antisense Therapeutics Company Information
13.2.2 Antisense Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.2.3 Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Antisense Therapeutics Main Business Overview
13.2.5 Antisense Therapeutics Latest Developments
13.3 Arbutus Biopharma
13.3.1 Arbutus Biopharma Company Information
13.3.2 Arbutus Biopharma Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.3.3 Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Arbutus Biopharma Main Business Overview
13.3.5 Arbutus Biopharma Latest Developments
13.4 Ionis Pharmaceuticals
13.4.1 Ionis Pharmaceuticals Company Information
13.4.2 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.4.3 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Ionis Pharmaceuticals Main Business Overview
13.4.5 Ionis Pharmaceuticals Latest Developments
13.5 F. Hoffmann-La Roche
13.5.1 F. Hoffmann-La Roche Company Information
13.5.2 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.5.3 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 F. Hoffmann-La Roche Main Business Overview
13.5.5 F. Hoffmann-La Roche Latest Developments
13.6 Santaris
13.6.1 Santaris Company Information
13.6.2 Santaris Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.6.3 Santaris Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Santaris Main Business Overview
13.6.5 Santaris Latest Developments
13.7 Silence Therapeutics
13.7.1 Silence Therapeutics Company Information
13.7.2 Silence Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.7.3 Silence Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Silence Therapeutics Main Business Overview
13.7.5 Silence Therapeutics Latest Developments
13.8 Sirnaomics
13.8.1 Sirnaomics Company Information
13.8.2 Sirnaomics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.8.3 Sirnaomics Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sirnaomics Main Business Overview
13.8.5 Sirnaomics Latest Developments
13.9 Tekmira Pharmaceuticals
13.9.1 Tekmira Pharmaceuticals Company Information
13.9.2 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.9.3 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Tekmira Pharmaceuticals Main Business Overview
13.9.5 Tekmira Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antisense and RNA Interference Therapeutics Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Antisense and RNA Interference Therapeutics by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Antisense and RNA Interference Therapeutics by Country/Region, 2018, 2022 & 2029
2.2 Antisense and RNA Interference Therapeutics Segment by Type
2.2.1 RNA
2.2.2 Antisense RNA
2.3 Antisense and RNA Interference Therapeutics Sales by Type
2.3.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
2.3.2 Global Antisense and RNA Interference Therapeutics Revenue and Market Share by Type (2018-2023)
2.3.3 Global Antisense and RNA Interference Therapeutics Sale Price by Type (2018-2023)
2.4 Antisense and RNA Interference Therapeutics Segment by Application
2.4.1 General Hospitals
2.4.2 Specialty Clinics
2.5 Antisense and RNA Interference Therapeutics Sales by Application
2.5.1 Global Antisense and RNA Interference Therapeutics Sale Market Share by Application (2018-2023)
2.5.2 Global Antisense and RNA Interference Therapeutics Revenue and Market Share by Application (2018-2023)
2.5.3 Global Antisense and RNA Interference Therapeutics Sale Price by Application (2018-2023)
3 GLOBAL ANTISENSE AND RNA INTERFERENCE THERAPEUTICS BY COMPANY
3.1 Global Antisense and RNA Interference Therapeutics Breakdown Data by Company
3.1.1 Global Antisense and RNA Interference Therapeutics Annual Sales by Company (2018-2023)
3.1.2 Global Antisense and RNA Interference Therapeutics Sales Market Share by Company (2018-2023)
3.2 Global Antisense and RNA Interference Therapeutics Annual Revenue by Company (2018-2023)
3.2.1 Global Antisense and RNA Interference Therapeutics Revenue by Company (2018-2023)
3.2.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Company (2018-2023)
3.3 Global Antisense and RNA Interference Therapeutics Sale Price by Company
3.4 Key Manufacturers Antisense and RNA Interference Therapeutics Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antisense and RNA Interference Therapeutics Product Location Distribution
3.4.2 Players Antisense and RNA Interference Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR ANTISENSE AND RNA INTERFERENCE THERAPEUTICS BY GEOGRAPHIC REGION
4.1 World Historic Antisense and RNA Interference Therapeutics Market Size by Geographic Region (2018-2023)
4.1.1 Global Antisense and RNA Interference Therapeutics Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Antisense and RNA Interference Therapeutics Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Antisense and RNA Interference Therapeutics Market Size by Country/Region (2018-2023)
4.2.1 Global Antisense and RNA Interference Therapeutics Annual Sales by Country/Region (2018-2023)
4.2.2 Global Antisense and RNA Interference Therapeutics Annual Revenue by Country/Region (2018-2023)
4.3 Americas Antisense and RNA Interference Therapeutics Sales Growth
4.4 APAC Antisense and RNA Interference Therapeutics Sales Growth
4.5 Europe Antisense and RNA Interference Therapeutics Sales Growth
4.6 Middle East & Africa Antisense and RNA Interference Therapeutics Sales Growth
5 AMERICAS
5.1 Americas Antisense and RNA Interference Therapeutics Sales by Country
5.1.1 Americas Antisense and RNA Interference Therapeutics Sales by Country (2018-2023)
5.1.2 Americas Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023)
5.2 Americas Antisense and RNA Interference Therapeutics Sales by Type
5.3 Americas Antisense and RNA Interference Therapeutics Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antisense and RNA Interference Therapeutics Sales by Region
6.1.1 APAC Antisense and RNA Interference Therapeutics Sales by Region (2018-2023)
6.1.2 APAC Antisense and RNA Interference Therapeutics Revenue by Region (2018-2023)
6.2 APAC Antisense and RNA Interference Therapeutics Sales by Type
6.3 APAC Antisense and RNA Interference Therapeutics Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antisense and RNA Interference Therapeutics by Country
7.1.1 Europe Antisense and RNA Interference Therapeutics Sales by Country (2018-2023)
7.1.2 Europe Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023)
7.2 Europe Antisense and RNA Interference Therapeutics Sales by Type
7.3 Europe Antisense and RNA Interference Therapeutics Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antisense and RNA Interference Therapeutics by Country
8.1.1 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Country (2018-2023)
8.1.2 Middle East & Africa Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023)
8.2 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Type
8.3 Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antisense and RNA Interference Therapeutics
10.3 Manufacturing Process Analysis of Antisense and RNA Interference Therapeutics
10.4 Industry Chain Structure of Antisense and RNA Interference Therapeutics
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antisense and RNA Interference Therapeutics Distributors
11.3 Antisense and RNA Interference Therapeutics Customer
12 WORLD FORECAST REVIEW FOR ANTISENSE AND RNA INTERFERENCE THERAPEUTICS BY GEOGRAPHIC REGION
12.1 Global Antisense and RNA Interference Therapeutics Market Size Forecast by Region
12.1.1 Global Antisense and RNA Interference Therapeutics Forecast by Region (2024-2029)
12.1.2 Global Antisense and RNA Interference Therapeutics Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Antisense and RNA Interference Therapeutics Forecast by Type
12.7 Global Antisense and RNA Interference Therapeutics Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Alnylam Pharmaceuticals
13.1.1 Alnylam Pharmaceuticals Company Information
13.1.2 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.1.3 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Alnylam Pharmaceuticals Main Business Overview
13.1.5 Alnylam Pharmaceuticals Latest Developments
13.2 Antisense Therapeutics
13.2.1 Antisense Therapeutics Company Information
13.2.2 Antisense Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.2.3 Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Antisense Therapeutics Main Business Overview
13.2.5 Antisense Therapeutics Latest Developments
13.3 Arbutus Biopharma
13.3.1 Arbutus Biopharma Company Information
13.3.2 Arbutus Biopharma Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.3.3 Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Arbutus Biopharma Main Business Overview
13.3.5 Arbutus Biopharma Latest Developments
13.4 Ionis Pharmaceuticals
13.4.1 Ionis Pharmaceuticals Company Information
13.4.2 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.4.3 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Ionis Pharmaceuticals Main Business Overview
13.4.5 Ionis Pharmaceuticals Latest Developments
13.5 F. Hoffmann-La Roche
13.5.1 F. Hoffmann-La Roche Company Information
13.5.2 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.5.3 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 F. Hoffmann-La Roche Main Business Overview
13.5.5 F. Hoffmann-La Roche Latest Developments
13.6 Santaris
13.6.1 Santaris Company Information
13.6.2 Santaris Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.6.3 Santaris Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Santaris Main Business Overview
13.6.5 Santaris Latest Developments
13.7 Silence Therapeutics
13.7.1 Silence Therapeutics Company Information
13.7.2 Silence Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.7.3 Silence Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Silence Therapeutics Main Business Overview
13.7.5 Silence Therapeutics Latest Developments
13.8 Sirnaomics
13.8.1 Sirnaomics Company Information
13.8.2 Sirnaomics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.8.3 Sirnaomics Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sirnaomics Main Business Overview
13.8.5 Sirnaomics Latest Developments
13.9 Tekmira Pharmaceuticals
13.9.1 Tekmira Pharmaceuticals Company Information
13.9.2 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
13.9.3 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Tekmira Pharmaceuticals Main Business Overview
13.9.5 Tekmira Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Antisense and RNA Interference Therapeutics Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Antisense and RNA Interference Therapeutics Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of RNA
Table 4. Major Players of Antisense RNA
Table 5. Global Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 6. Global Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Table 7. Global Antisense and RNA Interference Therapeutics Revenue by Type (2018-2023) & ($ million)
Table 8. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type (2018-2023)
Table 9. Global Antisense and RNA Interference Therapeutics Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 11. Global Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Table 12. Global Antisense and RNA Interference Therapeutics Revenue by Application (2018-2023)
Table 13. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application (2018-2023)
Table 14. Global Antisense and RNA Interference Therapeutics Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Antisense and RNA Interference Therapeutics Sales by Company (2018-2023) & (K Units)
Table 16. Global Antisense and RNA Interference Therapeutics Sales Market Share by Company (2018-2023)
Table 17. Global Antisense and RNA Interference Therapeutics Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Company (2018-2023)
Table 19. Global Antisense and RNA Interference Therapeutics Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Antisense and RNA Interference Therapeutics Producing Area Distribution and Sales Area
Table 21. Players Antisense and RNA Interference Therapeutics Products Offered
Table 22. Antisense and RNA Interference Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Antisense and RNA Interference Therapeutics Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Antisense and RNA Interference Therapeutics Sales Market Share Geographic Region (2018-2023)
Table 27. Global Antisense and RNA Interference Therapeutics Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Antisense and RNA Interference Therapeutics Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Antisense and RNA Interference Therapeutics Sales Market Share by Country/Region (2018-2023)
Table 31. Global Antisense and RNA Interference Therapeutics Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Antisense and RNA Interference Therapeutics Sales by Country (2018-2023) & (K Units)
Table 34. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Country (2018-2023)
Table 35. Americas Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2018-2023)
Table 37. Americas Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 38. Americas Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 39. APAC Antisense and RNA Interference Therapeutics Sales by Region (2018-2023) & (K Units)
Table 40. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Region (2018-2023)
Table 41. APAC Antisense and RNA Interference Therapeutics Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Antisense and RNA Interference Therapeutics Revenue Market Share by Region (2018-2023)
Table 43. APAC Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 44. APAC Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 45. Europe Antisense and RNA Interference Therapeutics Sales by Country (2018-2023) & (K Units)
Table 46. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Country (2018-2023)
Table 47. Europe Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2018-2023)
Table 49. Europe Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 50. Europe Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Antisense and RNA Interference Therapeutics
Table 58. Key Market Challenges & Risks of Antisense and RNA Interference Therapeutics
Table 59. Key Industry Trends of Antisense and RNA Interference Therapeutics
Table 60. Antisense and RNA Interference Therapeutics Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Antisense and RNA Interference Therapeutics Distributors List
Table 63. Antisense and RNA Interference Therapeutics Customer List
Table 64. Global Antisense and RNA Interference Therapeutics Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Antisense and RNA Interference Therapeutics Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Antisense and RNA Interference Therapeutics Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Antisense and RNA Interference Therapeutics Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Antisense and RNA Interference Therapeutics Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Antisense and RNA Interference Therapeutics Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Antisense and RNA Interference Therapeutics Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Antisense and RNA Interference Therapeutics Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Antisense and RNA Interference Therapeutics Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Antisense and RNA Interference Therapeutics Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Antisense and RNA Interference Therapeutics Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Antisense and RNA Interference Therapeutics Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Alnylam Pharmaceuticals Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 79. Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 80. Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Alnylam Pharmaceuticals Main Business
Table 82. Alnylam Pharmaceuticals Latest Developments
Table 83. Antisense Therapeutics Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 84. Antisense Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 85. Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Antisense Therapeutics Main Business
Table 87. Antisense Therapeutics Latest Developments
Table 88. Arbutus Biopharma Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 89. Arbutus Biopharma Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 90. Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Arbutus Biopharma Main Business
Table 92. Arbutus Biopharma Latest Developments
Table 93. Ionis Pharmaceuticals Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 94. Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 95. Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Ionis Pharmaceuticals Main Business
Table 97. Ionis Pharmaceuticals Latest Developments
Table 98. F. Hoffmann-La Roche Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 99. F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 100. F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. F. Hoffmann-La Roche Main Business
Table 102. F. Hoffmann-La Roche Latest Developments
Table 103. Santaris Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 104. Santaris Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 105. Santaris Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Santaris Main Business
Table 107. Santaris Latest Developments
Table 108. Silence Therapeutics Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 109. Silence Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 110. Silence Therapeutics Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Silence Therapeutics Main Business
Table 112. Silence Therapeutics Latest Developments
Table 113. Sirnaomics Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 114. Sirnaomics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 115. Sirnaomics Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Sirnaomics Main Business
Table 117. Sirnaomics Latest Developments
Table 118. Tekmira Pharmaceuticals Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 119. Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 120. Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Tekmira Pharmaceuticals Main Business
Table 122. Tekmira Pharmaceuticals Latest Developments
Table 1. Antisense and RNA Interference Therapeutics Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Antisense and RNA Interference Therapeutics Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of RNA
Table 4. Major Players of Antisense RNA
Table 5. Global Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 6. Global Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Table 7. Global Antisense and RNA Interference Therapeutics Revenue by Type (2018-2023) & ($ million)
Table 8. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type (2018-2023)
Table 9. Global Antisense and RNA Interference Therapeutics Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 11. Global Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Table 12. Global Antisense and RNA Interference Therapeutics Revenue by Application (2018-2023)
Table 13. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application (2018-2023)
Table 14. Global Antisense and RNA Interference Therapeutics Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Antisense and RNA Interference Therapeutics Sales by Company (2018-2023) & (K Units)
Table 16. Global Antisense and RNA Interference Therapeutics Sales Market Share by Company (2018-2023)
Table 17. Global Antisense and RNA Interference Therapeutics Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Company (2018-2023)
Table 19. Global Antisense and RNA Interference Therapeutics Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Antisense and RNA Interference Therapeutics Producing Area Distribution and Sales Area
Table 21. Players Antisense and RNA Interference Therapeutics Products Offered
Table 22. Antisense and RNA Interference Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Antisense and RNA Interference Therapeutics Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Antisense and RNA Interference Therapeutics Sales Market Share Geographic Region (2018-2023)
Table 27. Global Antisense and RNA Interference Therapeutics Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Antisense and RNA Interference Therapeutics Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Antisense and RNA Interference Therapeutics Sales Market Share by Country/Region (2018-2023)
Table 31. Global Antisense and RNA Interference Therapeutics Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Antisense and RNA Interference Therapeutics Sales by Country (2018-2023) & (K Units)
Table 34. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Country (2018-2023)
Table 35. Americas Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2018-2023)
Table 37. Americas Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 38. Americas Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 39. APAC Antisense and RNA Interference Therapeutics Sales by Region (2018-2023) & (K Units)
Table 40. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Region (2018-2023)
Table 41. APAC Antisense and RNA Interference Therapeutics Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Antisense and RNA Interference Therapeutics Revenue Market Share by Region (2018-2023)
Table 43. APAC Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 44. APAC Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 45. Europe Antisense and RNA Interference Therapeutics Sales by Country (2018-2023) & (K Units)
Table 46. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Country (2018-2023)
Table 47. Europe Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2018-2023)
Table 49. Europe Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 50. Europe Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Antisense and RNA Interference Therapeutics Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Antisense and RNA Interference Therapeutics
Table 58. Key Market Challenges & Risks of Antisense and RNA Interference Therapeutics
Table 59. Key Industry Trends of Antisense and RNA Interference Therapeutics
Table 60. Antisense and RNA Interference Therapeutics Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Antisense and RNA Interference Therapeutics Distributors List
Table 63. Antisense and RNA Interference Therapeutics Customer List
Table 64. Global Antisense and RNA Interference Therapeutics Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Antisense and RNA Interference Therapeutics Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Antisense and RNA Interference Therapeutics Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Antisense and RNA Interference Therapeutics Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Antisense and RNA Interference Therapeutics Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Antisense and RNA Interference Therapeutics Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Antisense and RNA Interference Therapeutics Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Antisense and RNA Interference Therapeutics Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Antisense and RNA Interference Therapeutics Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Antisense and RNA Interference Therapeutics Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Antisense and RNA Interference Therapeutics Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Antisense and RNA Interference Therapeutics Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Alnylam Pharmaceuticals Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 79. Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 80. Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Alnylam Pharmaceuticals Main Business
Table 82. Alnylam Pharmaceuticals Latest Developments
Table 83. Antisense Therapeutics Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 84. Antisense Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 85. Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Antisense Therapeutics Main Business
Table 87. Antisense Therapeutics Latest Developments
Table 88. Arbutus Biopharma Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 89. Arbutus Biopharma Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 90. Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Arbutus Biopharma Main Business
Table 92. Arbutus Biopharma Latest Developments
Table 93. Ionis Pharmaceuticals Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 94. Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 95. Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Ionis Pharmaceuticals Main Business
Table 97. Ionis Pharmaceuticals Latest Developments
Table 98. F. Hoffmann-La Roche Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 99. F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 100. F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. F. Hoffmann-La Roche Main Business
Table 102. F. Hoffmann-La Roche Latest Developments
Table 103. Santaris Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 104. Santaris Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 105. Santaris Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. Santaris Main Business
Table 107. Santaris Latest Developments
Table 108. Silence Therapeutics Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 109. Silence Therapeutics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 110. Silence Therapeutics Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Silence Therapeutics Main Business
Table 112. Silence Therapeutics Latest Developments
Table 113. Sirnaomics Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 114. Sirnaomics Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 115. Sirnaomics Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Sirnaomics Main Business
Table 117. Sirnaomics Latest Developments
Table 118. Tekmira Pharmaceuticals Basic Information, Antisense and RNA Interference Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 119. Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolios and Specifications
Table 120. Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Tekmira Pharmaceuticals Main Business
Table 122. Tekmira Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Antisense and RNA Interference Therapeutics
Figure 2. Antisense and RNA Interference Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antisense and RNA Interference Therapeutics Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Antisense and RNA Interference Therapeutics Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Antisense and RNA Interference Therapeutics Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of RNA
Figure 10. Product Picture of Antisense RNA
Figure 11. Global Antisense and RNA Interference Therapeutics Sales Market Share by Type in 2022
Figure 12. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type (2018-2023)
Figure 13. Antisense and RNA Interference Therapeutics Consumed in General Hospitals
Figure 14. Global Antisense and RNA Interference Therapeutics Market: General Hospitals (2018-2023) & (K Units)
Figure 15. Antisense and RNA Interference Therapeutics Consumed in Specialty Clinics
Figure 16. Global Antisense and RNA Interference Therapeutics Market: Specialty Clinics (2018-2023) & (K Units)
Figure 17. Global Antisense and RNA Interference Therapeutics Sales Market Share by Application (2022)
Figure 18. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application in 2022
Figure 19. Antisense and RNA Interference Therapeutics Sales Market by Company in 2022 (K Units)
Figure 20. Global Antisense and RNA Interference Therapeutics Sales Market Share by Company in 2022
Figure 21. Antisense and RNA Interference Therapeutics Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Company in 2022
Figure 23. Global Antisense and RNA Interference Therapeutics Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 26. Americas Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 27. APAC Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 28. APAC Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 29. Europe Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 30. Europe Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 32. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 33. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Country in 2022
Figure 34. Americas Antisense and RNA Interference Therapeutics Revenue Market Share by Country in 2022
Figure 35. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 36. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 37. United States Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Region in 2022
Figure 42. APAC Antisense and RNA Interference Therapeutics Revenue Market Share by Regions in 2022
Figure 43. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 44. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 45. China Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Country in 2022
Figure 53. Europe Antisense and RNA Interference Therapeutics Revenue Market Share by Country in 2022
Figure 54. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 55. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 56. Germany Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 65. Egypt Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Antisense and RNA Interference Therapeutics in 2022
Figure 71. Manufacturing Process Analysis of Antisense and RNA Interference Therapeutics
Figure 72. Industry Chain Structure of Antisense and RNA Interference Therapeutics
Figure 73. Channels of Distribution
Figure 74. Global Antisense and RNA Interference Therapeutics Sales Market Forecast by Region (2024-2029)
Figure 75. Global Antisense and RNA Interference Therapeutics Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Antisense and RNA Interference Therapeutics Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Antisense and RNA Interference Therapeutics Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Antisense and RNA Interference Therapeutics Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Antisense and RNA Interference Therapeutics Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Antisense and RNA Interference Therapeutics
Figure 2. Antisense and RNA Interference Therapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antisense and RNA Interference Therapeutics Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Antisense and RNA Interference Therapeutics Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Antisense and RNA Interference Therapeutics Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of RNA
Figure 10. Product Picture of Antisense RNA
Figure 11. Global Antisense and RNA Interference Therapeutics Sales Market Share by Type in 2022
Figure 12. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type (2018-2023)
Figure 13. Antisense and RNA Interference Therapeutics Consumed in General Hospitals
Figure 14. Global Antisense and RNA Interference Therapeutics Market: General Hospitals (2018-2023) & (K Units)
Figure 15. Antisense and RNA Interference Therapeutics Consumed in Specialty Clinics
Figure 16. Global Antisense and RNA Interference Therapeutics Market: Specialty Clinics (2018-2023) & (K Units)
Figure 17. Global Antisense and RNA Interference Therapeutics Sales Market Share by Application (2022)
Figure 18. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application in 2022
Figure 19. Antisense and RNA Interference Therapeutics Sales Market by Company in 2022 (K Units)
Figure 20. Global Antisense and RNA Interference Therapeutics Sales Market Share by Company in 2022
Figure 21. Antisense and RNA Interference Therapeutics Revenue Market by Company in 2022 ($ Million)
Figure 22. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Company in 2022
Figure 23. Global Antisense and RNA Interference Therapeutics Sales Market Share by Geographic Region (2018-2023)
Figure 24. Global Antisense and RNA Interference Therapeutics Revenue Market Share by Geographic Region in 2022
Figure 25. Americas Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 26. Americas Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 27. APAC Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 28. APAC Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 29. Europe Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 30. Europe Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 31. Middle East & Africa Antisense and RNA Interference Therapeutics Sales 2018-2023 (K Units)
Figure 32. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue 2018-2023 ($ Millions)
Figure 33. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Country in 2022
Figure 34. Americas Antisense and RNA Interference Therapeutics Revenue Market Share by Country in 2022
Figure 35. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 36. Americas Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 37. United States Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 38. Canada Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 39. Mexico Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 40. Brazil Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 41. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Region in 2022
Figure 42. APAC Antisense and RNA Interference Therapeutics Revenue Market Share by Regions in 2022
Figure 43. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 44. APAC Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 45. China Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 46. Japan Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 47. South Korea Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 48. Southeast Asia Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 49. India Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 50. Australia Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 51. China Taiwan Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 52. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Country in 2022
Figure 53. Europe Antisense and RNA Interference Therapeutics Revenue Market Share by Country in 2022
Figure 54. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 55. Europe Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 56. Germany Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 57. France Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 58. UK Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 59. Italy Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 60. Russia Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 61. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Country in 2022
Figure 62. Middle East & Africa Antisense and RNA Interference Therapeutics Revenue Market Share by Country in 2022
Figure 63. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Type (2018-2023)
Figure 64. Middle East & Africa Antisense and RNA Interference Therapeutics Sales Market Share by Application (2018-2023)
Figure 65. Egypt Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 66. South Africa Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 67. Israel Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 68. Turkey Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 69. GCC Country Antisense and RNA Interference Therapeutics Revenue Growth 2018-2023 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Antisense and RNA Interference Therapeutics in 2022
Figure 71. Manufacturing Process Analysis of Antisense and RNA Interference Therapeutics
Figure 72. Industry Chain Structure of Antisense and RNA Interference Therapeutics
Figure 73. Channels of Distribution
Figure 74. Global Antisense and RNA Interference Therapeutics Sales Market Forecast by Region (2024-2029)
Figure 75. Global Antisense and RNA Interference Therapeutics Revenue Market Share Forecast by Region (2024-2029)
Figure 76. Global Antisense and RNA Interference Therapeutics Sales Market Share Forecast by Type (2024-2029)
Figure 77. Global Antisense and RNA Interference Therapeutics Revenue Market Share Forecast by Type (2024-2029)
Figure 78. Global Antisense and RNA Interference Therapeutics Sales Market Share Forecast by Application (2024-2029)
Figure 79. Global Antisense and RNA Interference Therapeutics Revenue Market Share Forecast by Application (2024-2029)
